Article citationsMore>>

Aragón-Herrera, A., Moraña-Fernández, S., Otero-Santiago, M., Anido-Varela, L., Campos-Toimil, M., García-Seara, J., et al. (2023) The Lipidomic and Inflammatory Profiles of Visceral and Subcutaneous Adipose Tissues Are Distinctly Regulated by the SGLT2 Inhibitor Empagliflozin in Zucker Diabetic Fatty Rats. Biomedicine & Pharmacotherapy, 161, Article 114535.
https://doi.org/10.1016/j.biopha.2023.114535

has been cited by the following article:

• TITLE: Treatment of Metabolic Diseases by Modulating Autophagy: Current Strategies and Future Directions

  AUTHORS: Nuo Yu, Lishan Tang, Linfeng Mo, Wei Peng, Huihuang Shen, Xiaoying Mo, Qingfu Lai, Yanqing Tan

  KEYWORDS: Autophagy, Metabolic Diseases, Lifestyle Intervention, Pharmacological Modulation

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.13 No.8, August 7, 2025

  ABSTRACT: As a key process in maintaining cellular metabolic homeostasis, the targeted regulation of autophagy offers new insights into the treatment of metabolic disorders such as diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). This systematic review examines core strategies for regulating autophagy to improve metabolic disorders, including lifestyle interventions, pharmacological modulation and the use of natural compounds. It also analyses the scientific basis and clinical limitations of existing therapies and explores future directions in tissue-specific drug development, precision medicine applications and interdisciplinary technological integration. The aim is to provide a theoretical foundation and practical reference for the development of safer and more effective metabolic disease treatments, facilitating a shift from broad-spectrum intervention to precise modulation.